Sugi Predict

Sugi Predict / Compounds / SCHEMBL16340653

SCHEMBL16340653

SCHEMBL16340653

CC(=O)N[C@H]1CCCNC(=O)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)NC(CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCCCCCCCCCCCCCCC(=O)O)C(N)=O)NC(=O)CNC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)C(Cc2c[nH]cn2)NC(=O)[C@H](CCC(=O)O)NC1=O

nearest known ligand 0.53

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 11/20 0.53
▸ MDM2 Q00987 4/20 0.53
▸ GLP1R P43220 2/20 0.51
▸ MC4R P32245 1/20 0.51
▸ TSLP Q969D9 1/20 0.50
▸ F11 P03951 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14550441 0.93 MDM2 (0.58) IL23RMDM2GLP1RMC4R
SCHEMBL14552773 0.93 MDM2 (0.54) IL23RMDM2GLP1RMC4RTSLP
SCHEMBL14550392 0.92 TSLP (0.54) IL23RGLP1RTSLPF11
SCHEMBL16340886 0.92 MDM2 (0.54) IL23RMDM2MC4R
SCHEMBL16340953 0.92 MDM2 (0.54) IL23RMDM2MC4R
SCHEMBL16340741 0.91 MDM2 (0.56) IL23RMDM2GLP1RMC4R
SCHEMBL14550326 0.91 MDM2 (0.55) IL23RMDM2GLP1RMC4R
SCHEMBL16340625 0.91 IL23R (0.51) IL23RMDM2MC4RTSLP
SCHEMBL16340624 0.90 IL23R (0.52) IL23RMDM2MC4R
SCHEMBL16340396 0.90 IL23R (0.52) IL23RMDM2MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012432-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2013-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012432-A1 Peptides for Treatment of Obesity MC4R, GIPR, MC3R IL23R 698/4885MDM2 4657/4885GLP1R 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.